Jiangsu Recbio Technology Co., Ltd. — Investor Relations & Filings

Jiangsu Recbio Technology Co., Ltd. is an innovative vaccine company focused on the research, development, and commercialization of subunit vaccines. The company leverages proprietary technology platforms, including novel adjuvant systems, protein engineering, and immune evaluation. Recbio is one of the few global entities capable of independently developing and manufacturing a full spectrum of novel vaccine adjuvants. The portfolio comprises over ten differentiated innovative vaccines targeting major diseases such as cervical cancer (HPV), herpes zoster (shingles), and respiratory syncytial virus (RSV). Key pipeline assets in China Phase III clinical studies include the recombinant 9-valent HPV vaccine (REC603) and the novel adjuvant recombinant herpes zoster vaccine (REC610). Manufacturing facilities are designed to comply with WHO PQ and EU GMP standards, supporting clinical supply and future commercialization, notably including a high-capacity facility for the 9-valent HPV vaccine.